Proportion of patients who received PET or LET with pre-HCT CMV detected by CMV DNA PCR and median day of detection in the 90 days before HCT at each evaluated CMV DNA PCR threshold
| . | Any CMV detection within 7 to 90 d before HCT . | CMV detection ≥150 IU/mL within 7 to 90 d before HCT . | CMV detection ≥500 IU/mL within 7 to 90 d before HCT . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PET∗ (n = 1367) . | LET∗ (n = 342) . | PET∗ (n = 1367) . | LET∗ (n = 342) . | PET∗ (n = 1367) . | LET∗ (n = 342) . | |||||||
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| No | 1212 | 89% | 305 | 89% | 1314 | 96% | 326 | 95% | 1343 | 98% | 331 | 97% |
| Yes without anti-CMV treatment | 58 | 4% | 14 | 4% | ||||||||
| Yes with anti-CMV treatment | 97 | 7% | 23 | 7% | 53 | 4% | 16 | 5% | 24 | 2% | 11 | 3% |
| Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | |||||||
| Day of CMV onset closest to transplant (transplant day 0) ≤90 d before transplant | –14.0 (–23 to –6) | –12.5 (–25 to –8) | –20.0 (–33 to –10) | –15.0 (–21 to –8) | –32.0 (–43 to –20) | –21.0 (–41 to –18) | ||||||
| Day of CMV onset with maximum viral load (transplant day 0) ≤90 d before transplant | N/A | N/A | –26.0 (–52 to –16) | –21.0 (–34 to –15) | –39.0 (–70 to –20) | –22.0 (–41 to –18) | ||||||
| . | Any CMV detection within 7 to 90 d before HCT . | CMV detection ≥150 IU/mL within 7 to 90 d before HCT . | CMV detection ≥500 IU/mL within 7 to 90 d before HCT . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PET∗ (n = 1367) . | LET∗ (n = 342) . | PET∗ (n = 1367) . | LET∗ (n = 342) . | PET∗ (n = 1367) . | LET∗ (n = 342) . | |||||||
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| No | 1212 | 89% | 305 | 89% | 1314 | 96% | 326 | 95% | 1343 | 98% | 331 | 97% |
| Yes without anti-CMV treatment | 58 | 4% | 14 | 4% | ||||||||
| Yes with anti-CMV treatment | 97 | 7% | 23 | 7% | 53 | 4% | 16 | 5% | 24 | 2% | 11 | 3% |
| Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | |||||||
| Day of CMV onset closest to transplant (transplant day 0) ≤90 d before transplant | –14.0 (–23 to –6) | –12.5 (–25 to –8) | –20.0 (–33 to –10) | –15.0 (–21 to –8) | –32.0 (–43 to –20) | –21.0 (–41 to –18) | ||||||
| Day of CMV onset with maximum viral load (transplant day 0) ≤90 d before transplant | N/A | N/A | –26.0 (–52 to –16) | –21.0 (–34 to –15) | –39.0 (–70 to –20) | –22.0 (–41 to –18) | ||||||
Note that the most (75%) of any CMV detection occurred in the first 30 days before HCT, which approximates the recommended window for pre-HCT CMV surveillance during the pre-HCT workup period at our center (ie, 3-4 weeks before HCT).
IQR, interquartile range; LET, letermovir prophylaxis; PET, preemptive antiviral therapy; N/A, data unavilable.
Note that PET patients had a total of 2880 pre-HCT samples submitted for CMV DNA PCR testing; whereas LET patients had a total of 1234 pre-HCT samples submitted for CMV DNA PCR testing.